Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study

PURPOSE: Tumor expression of programmed death-ligand 1 (PD-L1) is associated with evasion of immune response in several types of malignancies and such expression may render patients eligible for PD-L1 inhibitors. The use of immune checkpoint blockade therapy has been recently approved for the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Nehad M, Fares, Mona, Marji, Raya, Al Bashir, Samir M, Yaghan, Rami J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597920/
https://www.ncbi.nlm.nih.gov/pubmed/34803400
http://dx.doi.org/10.2147/BCTT.S333123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597920/
https://www.ncbi.nlm.nih.gov/pubmed/34803400
http://dx.doi.org/10.2147/BCTT.S333123

Ejemplares similares